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Abstract
Background: The objective of this study was to evaluate and compare the evolution of the profile currently
recommended by the International Renal Interest Society (IRIS) (sCr, UPC and sSDMA) with a panel of other
different kidney biomarkers during treatment for canine leishmaniosis. This panel included three urinary glomerular
biomarkers (uIgG, uCRP and uferritin) and three urinary tubular biomarkers (uGGT, uNAG and uRBP).
These biomarkers were measured in two groups of dogs with canine leishmaniosis at IRIS stage I. Group 1: dogs
showing proteinuria (UPC > 0.5) before treatment which did not decrease after treatment; Group 2: dogs showing
proteinuria before treatment which decreased after treatment.
Results: Group 1 showed no significant changes in any biomarker after treatment. In group 2, among the
biomarkers recommended by the IRIS, only UPC showed a significant decrease after treatment. However all
biomarkers of glomerular damage showed a significant decrease after treatment, with uIgG/Cr and uCRP/Cr
showing the greater decreases. In addition uRBP/Cr and uNAG/Cr showed significant decreases after treatment.
Conclusions: In dogs with leishmaniosis at IRIS stage I that reduced UPC after treatment, there were no significant
changes in serum creatinine and sSDMA. However, all the urine biomarkers evaluated with exception of uGGT
showed a significant decrease. These decreases were more evident in those markers related with glomerular
function, being uIgG/Cr the biomarker more associated with UPC. Further studies involving a larger number of
animals and histological analysis of the kidney would be recommended to confirm these findings and evaluate the
routine practical use of these urine biomarkers in canine leishmaniosis.
Keywords: Urine, Kidney, Immunoglobulin G (IgG), UPC, Creatinine, Symmetric dimethylarginine (SDMA), Gamma
glutamyl-transpeptidase (GGT), Retinol-binding protein (RBP)
Background
Canine leishmaniosis is a disease that causes glomerulo-
nephritis and chronic kidney disease (CKD) by immune
complex deposition that may lead to end-stage renal fail-
ure [1, 2]. Initially, infected dogs can show proteinuria in
absence of azotemia. However, in case that glomerular
disease progresses, tubulointerstitial lesions, azotemia
and end-stage renal failure signs can appear [1]. In the
Mediterranean area, canine leishmaniosis is caused by
infection with Leishmania infantum transmitted by Phle-
botomus sand fly, and in countries such as Spain the
prevalence can reach to 67% in some areas [3].
Serum creatinine (sCr) and urinary protein to creatin-
ine ratio (UPC) are the biomarkers traditionally recom-
mended by the International Renal Interest Society
(IRIS) to evaluate and monitor renal damage/dysfunction
[4], and are used in the clinical classification of canine
leishmaniosis [5]. Recently, the measurement of serum
symmetric dimethylarginine (sSDMA) has also been rec-
ommended by IRIS. However, there are other biomarkers
that can be measured in urine and are useful for kidney
evaluation. These biomarkers are very sensitive to evaluate
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renal damage and additionally have the capacity to quan-
tify and localize the site of renal injury [6, 7]. For example,
immunoglobulin G (IgG) and the acute phase proteins C-
reactive protein (CRP) and ferritin are high molecular
weight proteins to which an intact glomerular barrier is
impermeable [8, 9]. Therefore the presence in urine of
these proteins would indicate a glomerular damage. In the
particular case of IgG it is considered to have a higher
specificity than UPC as a marker of the severity of damage
to the glomerular capillary wall. This is due to the fact that
IgG, contrarily to UPC, is not influenced by tubular
lesions [8].
On the other hand, there are proteins in urine that
can inform about the existence of tubular dysfunction.
For example, retinol-binding protein (RBP) is a low mo-
lecular weight protein (21-kDa) synthesized in the liver
[10], that can be detected in urine when there is a prox-
imal tubulointerstitial damage impairing reabsorption
[8]. In addition, N-aceytyl-β-D-glucosaminidase (NAG)
is described as a lysosomal enzyme in the renal tubular
epithelial cells that is released when renal damage occurs
and gamma glutamyl-transpeptidase (GGT) is related
with tubular damage and can identify dogs with tubular
proteinuria [11].
To the authors’ knowledge, there are no studies in
which the dynamics of the biomarkers recommended by
the IRIS during canine leishmaniosis treatment are ana-
lysed and compared with other different glomerular and
tubular biomarkers.
Therefore, the objective of this study was to evaluate
and compare the evolution of the profile currently recom-
mended by the IRIS (sCr, UPC and sSDMA) with a panel
of other different kidney biomarkers during treatment for
canine leishmaniosis. This panel included three urinary
glomerular biomarkers (uIgG, uCRP and uferritin)
and three urinary tubular biomarkers (uGGT, uNAG
and uRBP).
To the authors’ knowledge this is the first time in
which a comprehensive profile of renal biomarkers is
evaluated in urine in the treatment of canine leishmanio-
sis. In addition uRBG and sSDMA will be studied for
the first time in dogs with this disease.
The evaluation of these biomarkers could provide new
insights about how biomarkers representing different
parts of the kidney, respond to a conventional treatment
for canine leishmanosis. In addition, it could serve a
basis to identify new potential markers that could be
used for treatment monitoring of this disease.
Methods
Animals and sampling
This was a prospective multicenter study in which three
clinics of southern Spain were involved lasting from No-
vember 2014 to May 2015.
The inclusion criteria for the dogs were: (1) diagnosis
of canine leishmaniosis based on compatible clinical
and/or laboratory changes [5] and the presence of high
antibody titers (sample-to-positive ratio >1,1 calculated
by OD sample/OD Low Positive Control) against Leish-
mania (Leiscan® Leishmania ELISA Test, Laboratorio
Dr. Esteve S.A., Spain) and also positive on either cy-
tology or real-time PCR from bone marrow or lymph
node to detect the presence of the parasite; (2) absence
of canine heartworm, Anaplasma phagocytophylum,
Borrelia burgdorferi, and Ehrlichia canis antibodies using
a fast test (Canine SNAP 4Dx, IDEXX laboratories); (3)
inactive urine sediment; (4) not presenting with diseases
other than leishmaniosis that could cause glomerulopathy;
(5) being at stage I of the IRIS staging of CKD, with serum
creatinine <1.4 mg/dl and having proteinuria (UPC > 0.5).
Animals were excluded if they had been treated with
angiotensin-converting enzyme inhibitors or any other
drug in the 6 months prior to entering the study.
The dogs were evaluated at initial diagnosis and after
4 weeks of treatment with N-methylglucamine antimoni-
ate (MGA) (50 mg/kg SC, two times daily) and allopur-
inol (10 mg/kg PO BID). A clinical score based on the
severity of various clinical signs following a previous re-
ported criteria [12] was obtained at diagnosis and after
4 weeks of treatment.
Blood samples were collected from the cephalic vein,
placed in tubes containing a clotting activator, allowed
to clot at room temperature, and centrifuged (3000 g,
10 min) to obtain serum and were stored at –80 °C until
analysis. Urine samples were obtained by cystocentesis
(5 mL, 22-G needles) and centrifuged (300 g, 2 min).
Sediment was analyzed to exclude urine samples with
active sediment and the supernatant were stored at −80 °
C until analysis.
In addition, in order to obtain values of the different
urinary biomarkers in healthy dogs, blood and urine was
obtained from 10 healthy entire adult dogs. This group
of dogs was integrated by 7 males and 3 females of dif-
ferent breeds with ages between 2 and 14 years, that
come to the clinics for routine health controls or vaccin-
ation. All dogs show values of the hemogram and bio-
chemical profile inside the reference range of the
laboratory and were negative when serum was analyzed
with the leishmania ELISA test.
The experimental procedure was approved by the Ani-
mal Experimentation Committee of the University of
Murcia.
Group allocation
Based on the evolution of the UPC after treatment, dogs
were allocated into two groups: dogs that showed pro-
teinuria (UPC > 0.5) before treatment and whose pro-
teinuria increased or did not decrease after treatment
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(Group 1) and dogs that showed proteinuria (UPC > 0.5)
before treatment and whose proteinuria decreased with
treatment (Group 2).
Urine biomarkers analysis
Protein, creatinine, ferritin and CRP in urine were mea-
sured by previously described methods [9, 13].
Automated assays using commercial kits were used for
IgG and GGT (Beckman Coulter, Inc., Brea, CA, USA)
and RBP and NAG (Dyazime, Poway, CA, USA) measure-
ments. Analyses were performed in an automatic analyzer
(Olympus AU400, Hamburg, Germany). All four assays
when validated in urine showed inter and intra-assay im-
precision lower than 15% and linearity under dilution re-
sulted in linear regression equations with correlation
coefficients (R2) higher than 0.98 in all cases.
SDMA was measured by liquid chromatography-mass
spectrometry (LC-MS) following a previously described
method [14]. The LC-MS system consisted of an Agilent
1100 Series HPLC (Agilent Technologies, Santa Clara,
CA, USA) equipped connected to an Agilent Ion Trap
XCT Plus Mass Spectrometer (Agilent Technologies,
Santa Clara, CA, USA) using an electrospray interface
(ESI). This assay showed an inter and intra-assay impre-
cision lower than 4%, high linearity with serial dilutions
(R2 > 0.98) and recoveries after spiking different concen-
trations of SDMA to a canine serum were 96–103%.
Statistical analysis
Kolmogorov-Smirnov test was performed to assess the
normality of data, giving a nonparametric distribution.
Data were then log-transformed and paired t test was used
to compare values before and after treatment using a
statistical program (Graph Pad Prism v.6 for Windows).
Correlations between all parameters studied were deter-
mined using the Spearman correlation analysis. A P value
of <0.05 was considered statistically significant.
Results
Eighteen dogs naturally infected with Leishmania infan-
tum of different breeds, ages (range, 2 to 13 years) and
sex (13 males and 5 females all entire) were included in
this study. Results of clinical scores are presented in
Table 1. Initially all dogs included in the study had clin-
ical and laboratory signs compatible with leishmaniosis,
which were significantly reduced in all cases in response
to treatment with the exception of 2 animals in the
group 1: one dog initially had skin lesions and uveitis
and maintained these clinical signs and one dog initially
had skin lesions that worsened after treatment.
Results for the biomarkers recommended by the IRIS
group, glomerular biomarkers and tubular biomarkers
are presented in Tables 1, 2 and 3 respectively. No sig-
nificant differences were found in any of the analytes
when mean values of the two groups before the treat-
ment were compared.
In group 1, biomarkers recommended by IRIS group
(UPC, sCr and sSDMA) did not show statistically signifi-
cant changes after treatment. In addition, no significant
changes were observed in biomarkers of glomerular and
tubular damage.
In group 2, of the biomarkers recommended by
IRIS group, only UPC showed a significant decrease
(67.22%) after treatment. All biomarkers of glomerular
damage showed a significant decrease after treatment
that was more significant and of higher magnitude in
the case of urinary immunoglobulin G to creatinine
ratio (uIgG/Cr) (77.02%) and urinary C-reactive pro-
tein to creatinine ratio (uCRP/Cr) (79.16%). Regarding
the biomarkers of tubular damage, urinary retinol-
binding protein to creatinine ratio (uRBP/Cr) and
urinary N-aceytyl-β-D-glucosaminidase to creatinine
ratio (uNAG/Cr) showed a significant decrease after
treatment (65.08 and 58.02% respectively) and urinary
gamma glutamyl-transpeptidase (uGGT/Cr) did not
show any significant change. Correlations between all
analytes are depicted in Table 4. A positive significant
Table 1 Median, (25th and 75th percentiles) and percentage of median deviation between initial and follow-up samples of clinical
scoring and the biomarkers recommended by IRIS. Group 1: dogs that showed proteinuria (UPC > 0.5) before treatment which did
not decrease or even increased after treatment; Group 2: dogs that showed proteinuria (UPC > 0.5) before treatment which
decreased after treatment
Parameter Group 1 (n = 6) Group 2 (n = 12) Reference
values at
authors
laboratory
Inital Follow up % median
deviation
Inital Follow up % median
deviation
Clinical
Scoring
7 (6–8.2) 4 (2.5–4.2) −42 9 (3–15) 2 (0.5–7) −77
UPC 1.492 (0.669–5.401) 2.270 (0.817–6.815) 52.14 1.318 (0.830–3.087) 0.432 (0.215–1.038)*** −67.22 <0.2
sCr (mg/dL) 0.88 (0.55–1.04) 0.92 (0.55–1.06) 1.04 0.69 (0.51–0.92) 0.94 (0.66–1.09) 13.62 <1.4
sSDMA
(μg/dL)
10.40 (6.67–20.51) 9.91 (7.47–12.33) −9.52 10.95 (7.85–16.35) 11.15 (8.57–12.18) 1.01 <14
***P < 0.001 compared to baseline
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association was found between UPC and uIgG/Cr,
uCRP/Cr and uRBP/Cr.
Discussion
This study reports the changes in a panel of various kid-
ney biomarkers in dogs with leishmaniosis after treat-
ment with MGA and allopurinol. Biomarkers included
those recommended by the IRIS, and additional urinary
glomerular and tubular biomarkers previously used for
kidney evaluation in the dog. Two of the biomarkers rec-
ommended by the IRIS, namely sCr and UPC, were used
as inclusion criteria for the dogs, since only dogs with
sCr lower than 1.4 mg/dL and UPC higher than 0.5 were
included in the study. Therefore we selected dogs that
had proteinuria but no azotemia, being in stage I accord-
ing with the IRIS staging of CKD. This allowed us to
eliminate azotemia as a confounding factor and focus
our study to those biomarkers that could better reflect
and correlate with the evolvement of the proteinuria.
The evolution of UPC after treatment was used to div-
ide the dogs in two groups: dogs that showed a decrease
in UPC and dogs that did not show a decrease in UPC
after treatment. Therefore the dynamics of the analytes
in the different possible unfolding of UPC in dogs with
leishmaniosis after treatment were compared. The
existence of dogs that do not show an improvement in
UPC after a conventional treatment for canine leishma-
niosis has been previously described [15]. In our study
we found four of the six dogs in group 1 that showed an
improvement in clinical signs despite experiencing an in-
crease in UPC. This is in agreement with previous studies
that did not found a relationship between clinical signs
and UPC in dogs with leishmaniosis, with non-proteinuric
dogs showing clinical signs [16] and also with the personal
observation of the authors of the presence of dogs with
evident proteinuria but without clinical signs.
sSDMA, which is a biomarker recently recommended
by the IRIS group, did not show significant changes after
treatment in dogs that showed a decrease in UPC. There-
fore, although SDMA is considered as one of the most
sensitive serum biomarker to evaluate the glomerular fil-
tration rate [14] and it was increased in some dogs in this
study (considering 14 μg/dL as a cut-off point), its use for
monitoring the evolution of proteinuria after treatment in
dogs with leishmaniosis in IRIS stage I would be question-
able. This would be in line with a previous report in dogs
in which changes in proteinuria appeared before changes
in SDMA [17]. Probably the SDMA would be a better pre-
dictor of changes in creatinine values, as has been previ-
ously described [14], than variations in proteinuria.
Table 2 Median, (25th and 75th percentiles) and percentage of median deviation between initial and follow-up samples of bio-
markers of glomerular damage. Group 1: dogs that showed proteinuria (UPC > 0.5) before treatment which did not decrease or even
increased after treatment; Group 2: dogs that showed proteinuria (UPC > 0.5) before treatment which decreased after treatment
Parameter Group 1 (n = 6) Group 2 (n = 12) Control dogs
(n = 10)Inital Follow up % median
deviation
Inital Follow up % median
deviation
uIgG/Cr
(mg/g)
202.7 (31.1–4986.0) 81.5 (3.5–3603.0) -24.8 176.1 (36.6–2996.0) 40.4 (12.9–408.4)** −77.02 0.01 (0.008–0.018)
uCRP/Cr
(μg/g)
6.06 (1.87–29.1) 8.38 (1.78–16.1) 38.2 15.40 (4.624–74.67) 3.21 (2.48–5.09)** −79.16 1.03 (0.74–1.89)
uFerr/Cr
(μg/g)
27.1 (5.6–45.9) 31.5 (5.2–60.5) 16.2 23.48 (8.95–60.92) 13.71 (5.35–30.57)* −41.61 2.00 (0.58–3.44)
**P<0.01 compared to baseline, *P<0.05 compared to baseline
Table 3 Median, (25th and 75th percentiles) and percentage of median deviation between initial and follow-up samples of
biomarkers of tubular damage. In Group 1: dogs that showed proteinuria (UPC > 0.5) before treatment which did not decrease or
even increased after treatment; Group 2: dogs that showed proteinuria (UPC > 0.5) before treatment which decreased after
treatment
Parameter Group 1
(n = 6)
Group 2
(n = 12)
Control dogs
(n = 10)
Inital Follow up % median
deviation
Inital Follow up % median
deviation
uRBP/Cr
(mg/g)
0.880 (0.049–7.453) 0.506 (0.173–8.608) −42.5 0.484 (0.227–2.650) 0.169 (0.037–0.502)* −65.08 0.21 (0–0.99)
uNAG/Cr
(UI/g)
18.49 (4.35–98.82) 18.30 (5.64–28.57) −1.03 14.77 (5.31–28.32) 6.20 (3.84–14.56)* −58.02 7.97 (5.27–11.19)
uGGT/Cr
(UI/g)
31.3 (20.0–101.8) 28.4 (9.9–95.2) −9.26 15.38 (11.05–90.36) 10.78 (7.44–19.63) −29.91 10.99 (8.37–18.87)
*P<0.05 compared to baseline
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However, our study used a relatively low number of dogs
and further studies with a larger number of dogs should
be made to corroborate our findings.
When other glomerular biomarkers in addition to
UPC were studied (uIgG/Cr, uCRP/Cr and urinary
ferritin to creatinine ratio (uFerr/Cr)), all of them had a
significant decrease in the dogs that reduced the UPC
after treatment. uCRP/Cr and uIgG/Cr showed a higher
percentage of decrease after treatment than UPC, and
uIgG/Cr showed the highest correlation with UPC of all
the biomarkers studied. In a recent study, uIgG was
found to be highly positively correlated with CKD
caused by immune complex-mediated glomeruloneph-
ritis (ICGN) [18], which is the most common kidney le-
sion produced in leishmaniosis. These authors found
that although its sensitivity was lower, uIgG showed
higher specificity than UPC for detecting ICGN. In
addition uIgG was highly associated, as UPC did, with
ultrastructural glomerular damage evaluated by transmis-
sion electron microscopy. In our study, the glomerular
markers did not show significant changes in the dogs with
no decrease in UPC after treatment. Although in general
the data of group 1 due to the low number of dogs should
be taken with caution, we observed in 3 cases that uIgG/
Cr and uCRP/Cr decreased after treatment although UPC
did not decrease. Further studies should be undertaken
the elucidate the possible explanation of this finding.
Two tubular markers (uRBP/Cr and uNAG/Cr) showed a
significant decrease in dogs with reduced UPC, and in the
case of uRBP/Cr the magnitude of this decrease was similar
to UPC, being uRBP/Cr and UPC highly associated. uRBP
is described as a particularly promising marker of CKD
progression since it strongly correlates with histologic le-
sions at glomerular and tubular level [19]. None of the
tubular markers showed any significant changes in the dogs
with no reduction in UPC after treatment. Although trad-
itionally considered as tubular markers, uRBP/Cr and
uNAG/Cr are also moderately to strongly correlated with
glomerular lesions [18, 19] and even uNAG/Cr is strongly
correlated with glomerular damage but not with tubular
damage in chronic proteinuric nephropathy [18]. On the
other hand, the lack of a significant decrease in uGGT/Cr
found in the dogs that reduced UPC, could be explained by
the fact that this analyte is more related with tubular dys-
function [11].
We did not characterize if the proteinuria of the dogs
was glomerular, tubular or mixed –which should be con-
sidered as a limitation of our study-. However it could
be hypothesized that uRBP/Cr and uNAG/Cr are in-
creased in our study because they are correlated with
glomerular damage. Additionally a tubular dysfunction
could exist in the dogs of our study. This would be in
line with the findings that tubular damage commonly
occurs concurrently with glomerular damage in cases of
chronic kidney disease, and that in these cases damage
to one compartment of the kidney affect the other [18].
In cases of glomerulonephritis, proteinuria develops
which can result in tubular damage. In fact, it has been
reported that most dogs affected with leishmaniosis have
mixed (glomerular and tubular) proteinuria [11]. An-
other cause for the tubular dysfunction could be related
with the possibility of MGA to produce tubular damage
[20]. Further studies should be undertaken to elucidate
the mechanisms leading to tubular disfunction in canine
leishmaniosis and its evolution during treatment.
It is important to point out that this is a pilot study
and it has major limitations, such as the low number of
animals studied and the lack of histological analysis to
characterize the type of lesion of the dogs and to allow
studying the sensitivity and specificity of the different
biomarkers to detect and monitor kidney damage.
Conclusions
In dogs with leishmaniosis at IRIS stage I that re-
duced UPC after treatment, there were no significant
changes in serum creatinine and sSDMA. However
Table 4 Correlations between all analytes of our study
UPC sCr sSDMA uIgG/Cr uCRP/Cr uFerr/Cr uRBP/Cr uNAG/Cr uGGT/Cr
UPC 0.39 −0.09 0.75*** 0.50* 0.42 0.59** 0.43 0.35
sCr 0.39 0.12 0.39 −0.11 0.11 0.42 0.23 −0.22
sSDMA −0.09 0.12 0.15 −0.13 −0.29 −0.38 −0.04 −0.38
uIgG/Cr 0.75*** 0.39 0.15 0.08 0.31 0.47* 0.12 0.08
uCRP/Cr 0.50* −0.11 −0.13 0.08 0.69*** 0.54* 0.48* 0.31
uFerr/Cr 0.42 0.11 −0.29 0.31 0.69*** 0.63** 0,53* 0.53*
uRBP/Cr 0.59** 0.42 −0.38 0.47* 0.54* 0.63** 0.14 0.27
uNAG/Cr 0.43 0.23 −0.04 0.12 0.48* 0,53* 0.14 0.33
uGGT/Cr 0.35 −0.22 −0.38 0.08 0.31 0.53* 0.27 0.33
* P <0.05
** P <0.01
*** P <0.001
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all the urine biomarkers evaluated with the exception
of GGT/Cr showed a significant decrease. These de-
creases were more evident in those markers related
with glomerular function, being uIgG/Cr the bio-
marker more associated with UPC. Further studies
involving a larger number of animals and histological
analysis of the kidney would be recommended to
corroborate these findings and evaluate the routine
practical use of these urine biomarkers for the early
recognition of kidney damage in dogs with canine
leishmaniosis and for monitoring kidney status dur-
ing therapy.
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